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Intravenous immunoglobulins (IVIgs) are used for several indications, including autoimmune conditions. IVIg treatment is
associated with several possible adverse reactions including induction of a hypercoagulable state. We report a 76-year-old woman
treated with IVIg for myasthenia gravis, which developed chest pain and weakness following IVIg infusion. The symptoms were
associated with ST segment depression in V4–6 and elevated troponin levels. The patient was diagnosed with non-ST elevation
myocardialinfarction(NSTEMI).Thepatienthadnosigniﬁcantriskfactorbesidesageandacardiacperfusionscanwasinterpreted
as normal (the patient refused to undergo cardiac catheterization). This case is compatible with IVIg-induced hypercoagulability
resulting in NSTEMI. Cardiac evaluation should therefore be considered prior to initiation of IVIg treatment especially in patients
with multiple cardiovascular risks.
Copyright © 2009 Meir Mizrahi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Intravenous immune globulin (IVIg) is a solution of human
plasma-derivedimmunoglobulinsofoverathousanddonors
containing an extensive range of immune antibodies which
may serve in protecting against human pathogens and
foreign antigens. The mode of action of IVIg is complex
and involves several mechanisms that act in synergy [1]. The
therapeutic eﬀects of IVIg most likely reﬂect the functions
of natural antibodies in maintaining immune homeostasis
in healthy individuals. Diﬀerent doses of IVIg are used for
diﬀerent diseases, for example, in immunodeﬁcit disease the
preferred dose is 200–400mg/kg body weight, given approx-
imately every 3 weeks. On the other hand, “high doses” of
IVIg, 1-2g/kg, are used as an “immunomodulatory” agent
in autoimmune and inﬂammatory disorders [1]. Its capacity
to exert a variety of immunomodulating activities has led
to the growing use of IVIg in treating several immune-
mediated disorders and autoimmune diseases such as sys-
temic lupus erytematous (SLE), antiphospholipid syndrome
(APS), pemphigus, idiopathic thrombocytopenic purpura
(ITP), multiple sclerosis (MS), myasthenia gravis (MG),
Kawasaki syndrome, dermatomyositis (DM) polymyositis
(PM), juvenile dermatomyositis (JDM), systemic vasculi-
tides, adult Still’s disease, prevention of graft-versus-host
disease in recipients of allogeneic bone marrow transplants,
intestinal bleeding due to Henoch-Schonlein purpura and in
recurrent abortions [2–10].
The majorities of these adverse eﬀects attributed to IVIg
are mild, self-limited, and related to the speed of infusion.
These eﬀects include headache (50%), back pain (4–6%),
chills, myalgia (4%), cough (2%), fever (1%), or chest dis-
comfort and do not usually necessitate discontinuation of
therapy. Severe adverse reactions occur with an incidence of
< 5%andincludeasepticmeningitis,dermatologicreactions,
anaphylaxis, and renal tubular necrosis in patients with pre-
existing kidney disease and volume depletion [11, 12].
Although an association between IVIg administration
and myocardial infarction (MI) has not been yet established
in prospective clinical trials, clinical experience suggests that
elder individuals or those with ischemic heart disease are
potentially at risk for cardiac ischemia with IVIg adminis-
tration [13, 14].
We report a case of probable IVIg-induced acute MI
occurring during treatment for myasthenia gravis.2 Case Reports in Medicine
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2. Patient Description
A 76-year-old woman was admitted to the emergency room
(E.R) due to loss of consciousness (syncope) 2 hours follow-
ing IVIg administration. Her past medical history included
hypothyroidism, gastroesophageal reﬂux, right lumpectomy,
and myasthenia gravis (MG) which was diagnosed 5 months
earlier. The chronic medical treatment of the patient was
brotizolam 0.25mg/once daily, lorazepam 1mg/once daily,
simvastatin20mg/oncedaily,thyroxinesodium100mg/once
daily, amlodipine 5mg/once daily, acetyl salicylic acid
75mg/oncedaily,pyridostigmineBromi60mg/3timesaday.
After an MG diagnosis was made, physostigmine treatment
was initiated with partial response, after which additional
treatment was given with azathioprine 100mg/day. This was
discontinued due to diverticulosis, and the patient started
treatmentwith2mg/kgofIVIgoncemonthly(Gamimune—
Igs normal Human 30%). The patient was admitted on the
ﬁrst day of her 3th cycle of IVIg treatment.
Anamnesis revealed that when the IVIg infusion ended,
the patient felt extremely weak with dizziness and chest
pain. The patient denies any history of chest pain or
cardiac catheterization, smoking, hyperlipidemia, diabetes,
or a family history of cardiac disease.
On arrival to the E.R, her vital signs showed slight
orthostatic blood pressure with 113/80mm/Hg in the supine
position and 98/75mm/Hg in the upright position, heart
rate was 99bpm, the rest of her physical examination
was unremarkable; electrocardiogram (ECG) showed ST
depression and T wave inversion in the lateral (V4–V6)
and anterior wall (V2-3), which were not demonstrated
on a prior electrocardiogram examination (Figure 1). Blood
tests showed normal electrolytes levels with sodium levels
of 139mmol/L (Normal range 135–145mmol/L), potassium
levels of 3.6mmol/L (Normal range 3.5–5mmol/L), and
magnesium levels were 0.9mmol/L (Normal range 0.7–
0.95mmol/L); renal function was unremarkable with creati-
nine levels of 86μmol/L (Normal range 60–106μmol/L) and
urea levels of 5.2mmol/L (Normal range 3.3–6.5mmol/L),
liver function tests were in the normal range with ALT
levels of 31units/L (Normal range 6–53units/L), AST levels
of 58units/L (Normal range 2–60units/L), ALK.P levels of
69units/L (Normal range 40–130units/L), GGTP levels of
16units/L (Normal range 10–80units/L), and LDH levels
of 520units/L (Normal range 300–620units/L). Complete
blood count showed leukocytosis of 15.1 10E9/l (Normal
range 4–10 10E9/l), with 88% neutrophilis, thrombocy-
topenia of 111 10E9/l (Normal range 140–400 10E9/l),
hemoglobin (Hb) level on patient’s arrival was 15.1g/dL
(Normal range 12–15g/dL) when the patient base line levels
are 12g/dL and hematocrit (Hct) levels of 42.4 (Normal
range 38–52%). Erythrocyte sedimentation rate (ESR) was
45mm/h, C-reactive protein (CRP) was 2.3 (N-0.5). Cardiac
markers showed elevated troponin T levels of 0.331ng/mL
(Normalrange0-0.1ng/mL) andonrepeatedtesting aftersix
hours, a rise in troponin T levels was seen up to 0.478ng/mL.
The patient was admitted to the cardiology department
with a diagnosis of non-ST elevation MI (NSTEMI) and was
treatedwithfullanticoagulation—enoxaparinof60mgtwice
a day and clopidogrel 75mg/day (after a 300mg loading
dose), β-blockers such as metoprolol 12.5mg twice daily,
ACE-I as ramipril 2.5mg once daily and acetyl salicylic acid
100mg/day.
During hospitalization the patient was oﬀered cardiac
catheterization,whichsherefused.Sheunderwentathallium
cardiac scan which was interpreted as normal. In light of
normal thallium cardiac scan and a stable clinical course,
the patient was discharged after 6 days and a follow-up in
the cardiology clinic was recommended. Ten days after the
initial event the patient underwent cardiac tomography with
noevidenceofcoronarydiseaseandcalciumindexwasinthe
normal range.
3. Discussion
We report here a rare case of non-ST elevation myocardial
infractionafterIVIgtreatment.Althoughseveralcasereports
of myocardial infraction after the use of IVIg were published,
it is not generally considered an adverse eﬀect of IVIg
[13–15]. Rapid administration of IVIg may cause ﬂushing,
altered heart rate, blood pressure. Medical literature showed
a very low rate of venues thromboembolic events in young
patients with MS treated with low-rate infusion [16]. The
recommended initial infusion rate is 0.5mL/kg/h for a 5%
IVIg solution and may be titrated up to 4mL/kg/h as
tolerated [16].
The pathophysiology of IVIg-induced thrombosis is not
well recognized. Proposed mechanisms consist of platelet
or endothelial cell activation and increased blood viscos-
ity, which is a signiﬁcant determinant of subendocardial
oxygen delivery [17, 18]. Other proposed mechanisms
includeincreasedreleaseofvasoconstrictivecytokinesand/or
arterial vasospasm caused by IVIg, which can contribute
to thrombotic events [19], in patient with Guillain-Barr´ e
Syndrome, specially in adult patient the use of IVIg can
provoke Reversible posterior leukoencephalopathy, cerebral
vasoconstriction, and strokes; cases in pediatric patients
were described also in [20, 21]. Dalakas et al. reported an
increase in viscosity after IVIg from 0.1 to 1 centipoise
in 13 patients, with the increase being higher in patients
with paraproteinaemic polyneuropathy and recommended
monitoring of serum viscosity in elderly patients and in
those with paraproteinaemias, high lipoproteins values, orCase Reports in Medicine 3
pre-existing vascular diseases. On the other hand slow infu-
sion rate and young age are optimal conditions for low risk
of VTE post-IVIg infusion [15–19].
We recognize that our patient may have had characteris-
tics complicating the clarity of a direct relation between IVIg
administration and acute MI (a direct causal relationship
between IVIg administration and myocardial infarction was
not proved with certatinty). Nevertheless, the fact that our
patient was free of prior ischemic heart disease, with a
normal Thallium scan and a negative cardiac tomography
test result, after the initial event, increases the likelihood of a
direct connection between higher blood viscosity dueto IVIg
administration and the cardiac event. Therefore, suggesting
a temporary ischemic mechanism, possibly a transient
increase in viscosity or reactive vasospasm similar to the
mechanism which provokes posterior leukoencephalopathy
and vasoconstriction in Guillain-Barr´ e Syndrome patients
treated with IVIg. Further treatment with IVIg with higher
rate of hydration and slower rate of drug administration did
not reproduce this ischemic episode in our patient.
4. Conclusion
Frank coronary events due to IVIg administration are
still considered rare. It is diﬃcult to ascertain the true
incidence of MI and other thrombotic complications of this
treatment, as many similar cases remain unpublished and
those cases which are reported are highly variable in the
details provided, therefore limiting informed conclusions.
Cardiovascular evaluation is not routinely performed before
IVIg treatment; however, it is recommended to be taken into
considerationinelderlypatientswithmultipleriskfactorsfor
cardiovascular disease who are candidates for IVIg treatment
according to the published recommended rate and dosage.
Furthermoreinthosepatientsthecardiacmonitoring during
the IVIg treatment needs to be considered.
Abbreviations
IVIg: Intravenous immunoglobulin
NSTEMI: Non-ST elevation
ER: Emergency room
ECG: Electrocardiogram
MG: Myasthenia gravis.
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